Expert Review of Vaccines最新文献_第2页

Multiple antigen presenting system (MAPS): state of the art and potential applications. 多重抗原递呈系统（MAPS）：最新技术和潜在应用。

IF 6.2 3区医学

Expert Review of Vaccines Pub Date : 2024-01-01 Epub Date: 2024-01-08 DOI: 10.1080/14760584.2023.2299384

Richard Malley, Ying-Jie Lu, Shite Sebastian, Fan Zhang, David O Willer

{"title":"Multiple antigen presenting system (MAPS): state of the art and potential applications.","authors":"Richard Malley, Ying-Jie Lu, Shite Sebastian, Fan Zhang, David O Willer","doi":"10.1080/14760584.2023.2299384","DOIUrl":"10.1080/14760584.2023.2299384","url":null,"abstract":"Introduction: Technological innovations have been instrumental in advancing vaccine design and protective benefit. Improvements in the safety, tolerability, and efficacy/effectiveness profiles have profoundly reduced vaccine-preventable global disease morbidity and mortality. Here we present an original vaccine platform, the Multiple Antigen Presenting System (MAPS), that relies on high-affinity interactions between a biotinylated polysaccharide (PS) and rhizavidin-fused pathogen-specific proteins. MAPS allows for flexible combinations of various PS and protein components.Areas covered: This narrative review summarizes the underlying principles of MAPS and describes its applications for vaccine design against bacterial and viral pathogens in non-clinical and clinical settings.Expert opinion: The utilization of high-affinity non-covalent biotin-rhizavidin interactions in MAPS allows for combining multiple PS and disease-specific protein antigens in a single vaccine. The modular design enables a simplified exchange of vaccine components. Published studies indicate that MAPS technology may support enhanced immunogenic breadth (covering more serotypes, inducing B- and T-cell responses) beyond that which may be elicited via PS- or protein-based conjugate vaccines. Importantly, a more detailed characterization of MAPS-based candidate vaccines is warranted, especially in clinical studies. It is anticipated that MAPS-based vaccines could be adapted and leveraged across numerous diseases of global public health importance.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":null,"pages":null},"PeriodicalIF":6.2,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139086553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Generation of the therapeutic monoclonal antibody NEO-201, derived from a cancer vaccine, which targets human malignancies and immune suppressor cells. 从癌症疫苗中提取治疗性单克隆抗体 NEO-201，该抗体针对人类恶性肿瘤和免疫抑制细胞。

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2024-01-01 Epub Date: 2024-09-01 DOI: 10.1080/14760584.2024.2397011

Massimo Fantini, Kwong Y Tsang, Philip M Arlen

{"title":"Generation of the therapeutic monoclonal antibody NEO-201, derived from a cancer vaccine, which targets human malignancies and immune suppressor cells.","authors":"Massimo Fantini, Kwong Y Tsang, Philip M Arlen","doi":"10.1080/14760584.2024.2397011","DOIUrl":"10.1080/14760584.2024.2397011","url":null,"abstract":"Introduction: Cancer vaccines stimulate the activation of specific humoral and cellular adaptive responses against cancer cells.Antibodies generated post vaccination can be isolated and further selected to develop highly specific and potent monoclonal antibodies (mAbs) against tumor-associated antigens.Areas covered: This review describes different types of cancer vaccines, the process of the generation of the mAb NEO-201 from the Hollinshead cancer vaccine platform, the characterization of the antigen recognized by NEO-201, the ability of NEO-201 to bind and mediate the killing of cancer cells and immunosuppressive cells (gMDSCs and Tregs) through ADCC and CDC, NEO-201 preclinical and clinical toxicity and efficacy.Expert opinion: To overcome the problem of poor clinical efficacy of cancer vaccines, due to the activity of immunosuppressive cells, cancer vaccines could be combined with other immunotherapeutics able to deplete immunosuppressive cells. Results from clinical trials, employing NEO-201 alone or in combination with pembrolizumab, showed that durable stabilization of disease after treatment was due to the ability of NEO-201 to target and reduce the percentage of circulating Tregs and gMDSCs.These findings provide compelling support to combine NEO-201 with cancer vaccines to reintegrate their ability to elicit a robust and durable immune adaptive response against cancer.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":null,"pages":null},"PeriodicalIF":5.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142055333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Modeling undetected poliovirus circulation following the 2022 outbreak in the United States. 2022 年美国爆发脊髓灰质炎疫情后未被发现的脊髓灰质炎病毒传播模型。

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2024-01-01 Epub Date: 2024-01-04 DOI: 10.1080/14760584.2023.2299401

Dominika A Kalkowska, Kamran Badizadegan, Janell A Routh, Cara C Burns, Eli S Rosenberg, I Ravi Brenner, Jane R Zucker, Marisa Langdon-Embry, Kimberly M Thompson

{"title":"Modeling undetected poliovirus circulation following the 2022 outbreak in the United States.","authors":"Dominika A Kalkowska, Kamran Badizadegan, Janell A Routh, Cara C Burns, Eli S Rosenberg, I Ravi Brenner, Jane R Zucker, Marisa Langdon-Embry, Kimberly M Thompson","doi":"10.1080/14760584.2023.2299401","DOIUrl":"10.1080/14760584.2023.2299401","url":null,"abstract":"Background: New York State (NYS) reported a polio case (June 2022) and outbreak of imported type 2 circulating vaccine-derived poliovirus (cVDPV2) (last positive wastewater detection in February 2023), for which uncertainty remains about potential ongoing undetected transmission.Research design and methods: Extending a prior deterministic model, we apply an established stochastic modeling approach to characterize the confidence about no circulation (CNC) of cVDPV2 as a function of time since the last detected signal of transmission (i.e. poliovirus positive acute flaccid myelitis case or wastewater sample).Results: With the surveillance coverage for the NYS population majority and its focus on outbreak counties, modeling suggests a high CNC (95%) within 3-10 months of the last positive surveillance signal, depending on surveillance sensitivity and population mixing patterns. Uncertainty about surveillance sensitivity implies longer durations required to achieve higher CNC.Conclusions: In populations that maintain high overall immunization coverage with inactivated poliovirus vaccine (IPV), rare polio cases may occur in un(der)-vaccinated individuals. Modeling demonstrates the unlikeliness of type 2 outbreaks reestablishing endemic transmission or resulting in large absolute numbers of paralytic cases. Achieving and maintaining high immunization coverage with IPV remains the most effective measure to prevent outbreaks and shorten the duration of imported poliovirus transmission.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":null,"pages":null},"PeriodicalIF":5.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11284832/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139073821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Modeling the potential public health and economic impact of different COVID-19 booster dose vaccination strategies with an adapted vaccine in the United Kingdom. 模拟在英国使用改良疫苗接种不同 COVID-19 强化剂量疫苗策略可能产生的公共卫生和经济影响。

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2024-01-01 Epub Date: 2024-08-05 DOI: 10.1080/14760584.2024.2383343

Cale Harrison, Rebecca Butfield, Ben Yarnoff, Jingyan Yang

{"title":"Modeling the potential public health and economic impact of different COVID-19 booster dose vaccination strategies with an adapted vaccine in the United Kingdom.","authors":"Cale Harrison, Rebecca Butfield, Ben Yarnoff, Jingyan Yang","doi":"10.1080/14760584.2024.2383343","DOIUrl":"10.1080/14760584.2024.2383343","url":null,"abstract":"Background: Updating vaccines is essential for combatting emerging coronavirus disease 2019 (COVID-19) variants. This study assessed the public health and economic impact of a booster dose of an adapted vaccine in the United Kingdom (UK).Methods: A Markov-decision tree model estimated the outcomes of vaccination strategies targeting various age and risk groups in the UK. Age-specific data derived from published sources were used. The model estimated case numbers, deaths, hospitalizations, medical costs, and societal costs. Scenario analyses were conducted to explore uncertainty.Results: Vaccination targeting individuals aged ≥ 65 years and the high-risk population aged 12-64 years was estimated to avert 701,549 symptomatic cases, 5,599 deaths, 18,086 hospitalizations, 56,326 post-COVID condition cases, and 38,263 lost quality-adjusted life years (QALYs), translating into direct and societal cost savings of £112,174,054 and £542,758,682, respectively. The estimated economically justifiable price at willingness-to-pay thresholds of £20,000 and £30,000 per QALY was £43 and £61, respectively, from the payer perspective and £64 and £82, respectively, from the societal perspective. Expanding to additional age groups improved the public health impact.Conclusions: Targeting individuals aged ≥ 65 years and those aged 12-64 years at high risk yields public health gains, but expansion to additional age groups provides additional gains.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":null,"pages":null},"PeriodicalIF":5.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141787682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immune mechanisms targeting malaria transmission: opportunities for vaccine development. 针对疟疾传播的免疫机制：疫苗开发的机遇。

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2024-01-01 Epub Date: 2024-06-25 DOI: 10.1080/14760584.2024.2369583

Geetha P Bansal, Nirbhay Kumar

{"title":"Immune mechanisms targeting malaria transmission: opportunities for vaccine development.","authors":"Geetha P Bansal, Nirbhay Kumar","doi":"10.1080/14760584.2024.2369583","DOIUrl":"10.1080/14760584.2024.2369583","url":null,"abstract":"Introduction: Malaria continues to remain a major global health problem with nearly a quarter of a billion clinical cases and more than 600,000 deaths in 2022. There has been significant progress toward vaccine development, however, poor efficacy of approved vaccines requiring multiple immunizing doses emphasizes the need for continued efforts toward improved vaccines. Progress to date, nonetheless, has provided impetus for malaria elimination.Areas covered: In this review we will focus on diverse immune mechanisms targeting gametocytes in the human host and gametocyte-mediated malaria transmission via the mosquito vector.Expert opinion: To march toward the goal of malaria elimination it will be critical to target the process of malaria transmission by mosquitoes, mediated exclusively by the sexual stages, i.e. male, and female gametocytes, ingested from infected vertebrate host. Studies over several decades have established antigens in the parasite sexual stages developing in the mosquito midgut as attractive targets for the development of transmission blocking vaccines (TBVs). Immune clearance of gametocytes in the vertebrate host can synergize with TBVs and directly aid in maintaining effective transmission reducing immune potential.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":null,"pages":null},"PeriodicalIF":5.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11472754/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141418564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immunogenicity and safety of Vero cell culture-derived Japanese encephalitis vaccine: a phase 3 study in Chinese infants. 源于 Vero 细胞培养的日本脑炎疫苗的免疫原性和安全性：中国婴儿的 3 期研究。

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2024-01-01 Epub Date: 2024-09-24 DOI: 10.1080/14760584.2024.2404633

Huanhuan Wang, Juan Wang, Shijie Yan, Gengfan Zhao, Shanzhen Wang, Hong Tao, Ye Xu, Jinfeng Wu

{"title":"Immunogenicity and safety of Vero cell culture-derived Japanese encephalitis vaccine: a phase 3 study in Chinese infants.","authors":"Huanhuan Wang, Juan Wang, Shijie Yan, Gengfan Zhao, Shanzhen Wang, Hong Tao, Ye Xu, Jinfeng Wu","doi":"10.1080/14760584.2024.2404633","DOIUrl":"10.1080/14760584.2024.2404633","url":null,"abstract":"Background: Japanese encephalitis (JE) is a severe infectious disease of the central nervous system. Vaccination with Vero cell culture-derived vaccines may effectively reduce JE incidence.Research design and methods: In this single-center, randomized, blinded, positive-controlled clinical trial in China involving 600 healthy infants aged 6-11 months, participants were divided into experimental and control groups administered JEV-PI and JEV-LI, respectively. Antibody titers were determined after 0- and 7-day immunization schedules. A booster dose followed 12 months later.Results: After primary vaccination and before booster vaccination, the positive conversion rate, geometric mean titer (GMT), and geometric mean increase (GMI) of JEV-PI-neutralizing antibodies exceeded those of JEV-LI. After booster immunization, the GMT and GMI of JEV-PI were higher than those of JEV-LI. After primary immunization, the local, systemic, and overall adverse reactions were of grades 1 and 2, with a low incidence of grade 3. After booster immunization, these differences were mainly grades 1 and 2, with no differences between JEV-PI and JEV-LI.Conclusion: JEV-PI is a promising vaccine as infants acquired long-lasting and highly neutralizing immune antibodies after inoculation with JEV-PI.Trial registration: The trial was registered in the Chinese Clinical Trial Registry (https://www.chictr.org.cn/showproj.html?proj = 203130; registration number: ChiCTR2300074692; registration date: 14/08/2023).","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":null,"pages":null},"PeriodicalIF":5.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142282791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cost-effectiveness of cell-based influenza vaccine in France. 法国细胞流感疫苗的成本效益。

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2024-01-01 Epub Date: 2024-10-24 DOI: 10.1080/14760584.2024.2417854

Gaetan Gavazzi, Marc Paccalin, Quentin Berkovitch, Henri Leleu, Romain Moreau, Emanuele Ciglia, Nansa Burlet, Joaquin Mould-Quevedo

{"title":"Cost-effectiveness of cell-based influenza vaccine in France.","authors":"Gaetan Gavazzi, Marc Paccalin, Quentin Berkovitch, Henri Leleu, Romain Moreau, Emanuele Ciglia, Nansa Burlet, Joaquin Mould-Quevedo","doi":"10.1080/14760584.2024.2417854","DOIUrl":"10.1080/14760584.2024.2417854","url":null,"abstract":"Objectives: Annually in France, influenza results in over one million GP consultations, around 20,000 hospitalizations, and approximately 9,000 deaths. This study assesses the cost-effectiveness of cell-based quadrivalent influenza vaccine (QIVc) for those under 65, which enhances effectiveness avoiding egg-adaptation, compared to egg-based quadrivalent influenza vaccine (QIVe).Methods: An age-structured susceptible-exposed-infected-recovered (SEIR) transmission model, calibrated to represent an average influenza season based on French data from 2011 to 2019, integrates a contact matrix estimating intergroup contact rates. Evaluating epidemiological, economic and utility outcomes, the model includes vaccine effectiveness and medical costs from the existing literature and French national data. Adjustments to quality of life due to infection and hospitalization are also included. Uncertainty is explored through scenario and sensitivity analyses.Results: Compared to QIVe, QIVc significantly reduces healthcare utilization and mortality, preventing 49,946 GP consultations, 1,087 hospitalizations, and 231 deaths in France. Despite an initial investment of 7.6 million euros, QIVc achieves a net saving of 12 million euros in healthcare expenditures, making it a dominant cost-saving strategy. Probabilistic sensitivity analyses indicate dominance in 78% of 10,000 simulations.Conclusions: Introducing cell-based influenza vaccines in the French immunization program prevents influenza cases, hospitalizations, death, while reducing costs versus egg-based influenza vaccines.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":null,"pages":null},"PeriodicalIF":5.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142461605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The important lessons lurking in the history of meningococcal epidemiology. 脑膜炎球菌流行病学史中潜藏的重要教训。

IF 6.2 3区医学

Expert Review of Vaccines Pub Date : 2024-01-01 Epub Date: 2024-04-04 DOI: 10.1080/14760584.2024.2329618

Ray Borrow, Jamie Findlow

{"title":"The important lessons lurking in the history of meningococcal epidemiology.","authors":"Ray Borrow, Jamie Findlow","doi":"10.1080/14760584.2024.2329618","DOIUrl":"10.1080/14760584.2024.2329618","url":null,"abstract":"Introduction: The epidemiology of invasive meningococcal disease (IMD), a rare but potentially fatal illness, is typically described as unpredictable and subject to sporadic outbreaks.Areas covered: Meningococcal epidemiology and vaccine use during the last ~ 200 years are examined within the context of meningococcal characterization and classification to guide future IMD prevention efforts.Expert opinion: Historical and contemporary data highlight the dynamic nature of meningococcal epidemiology, with continued emergence of hyperinvasive clones and affected regions. Recent shifts include global increases in serogroup W disease, meningococcal antimicrobial resistance (AMR), and meningococcal urethritis; additionally, unvaccinated populations have experienced disease resurgences following lifting of COVID-19 restrictions. Despite these changes, a close analysis of meningococcal epidemiology indicates consistent dominance of serogroups A, B, C, W, and Y and elevated IMD rates among infants and young children, adolescents/young adults, and older adults. Demonstrably effective vaccines against all 5 major disease-causing serogroups are available, and their prophylactic use represents a powerful weapon against IMD, including AMR. The World Health Organization's goal of defeating meningitis by the year 2030 demands broad protection against IMD, which in turn indicates an urgent need to expand meningococcal vaccination programs across major disease-causing serogroups and age-related risk groups.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":null,"pages":null},"PeriodicalIF":6.2,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140189626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evidence for a 10-year TBE vaccine booster interval: an evaluation of current data. 间隔 10 年加强接种 TBE 疫苗的证据：对当前数据的评估。

IF 6.2 3区医学

Expert Review of Vaccines Pub Date : 2024-01-01 Epub Date: 2024-02-16 DOI: 10.1080/14760584.2024.2311359

Jörg Schelling, Suzanne Einmahl, Ralph Torgler, Carsten Schade Larsen

{"title":"Evidence for a 10-year TBE vaccine booster interval: an evaluation of current data.","authors":"Jörg Schelling, Suzanne Einmahl, Ralph Torgler, Carsten Schade Larsen","doi":"10.1080/14760584.2024.2311359","DOIUrl":"10.1080/14760584.2024.2311359","url":null,"abstract":"Introduction: Tick-borne encephalitis (TBE) is rapidly spreading to new areas in many parts of Europe. While vaccination remains the most effective method of protection against the disease, vaccine uptake is low in many endemic countries.Areas covered: We conducted a literature search of the MEDLINE database to identify articles published from 2018 to 2023 that evaluated the immunogenicity and effectiveness of TBE vaccines, particularly Encepur, when booster doses were administered up to 10 years apart. We searched PubMed with the MeSH terms 'Encephalitis, Tick-Borne/prevention and control' and 'Vaccination' for articles published in the English language.Expert opinion: Long-term immunogenicity data for Encepur and real-world data on vaccine effectiveness and breakthrough infections following the two European TBE vaccines, Encepur and FSME-Immun, have shown that extending the booster interval from 3-5 years to 10 years does not negatively impact protection against TBE, regardless of age. Such extension not only streamlines the vaccination schedules but may also increase vaccine uptake and compliance among those living in endemic regions.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":null,"pages":null},"PeriodicalIF":6.2,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139575525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Regional molecular epidemiology of dengue and the potential optimization of its control through the use of vaccines. Report of the Arbovirus Committee of the Latin American Society of Pediatric Infectious Diseases, SLIPE. 登革热的地区分子流行病学以及通过使用疫苗优化控制的可能性。拉丁美洲儿科传染病学会虫媒病毒委员会（SLIPE）的报告。

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2024-01-01 Epub Date: 2024-08-29 DOI: 10.1080/14760584.2024.2395550

Jaime R Torres, Jose Brea-Del Castillo, Xavier Saez-Llorens, María L Ávila-Agüero, Wilfrido Coronell R, Celia Martinez-De Cuellar, Roberto Debbag

{"title":"Regional molecular epidemiology of dengue and the potential optimization of its control through the use of vaccines. Report of the Arbovirus Committee of the Latin American Society of Pediatric Infectious Diseases, SLIPE.","authors":"Jaime R Torres, Jose Brea-Del Castillo, Xavier Saez-Llorens, María L Ávila-Agüero, Wilfrido Coronell R, Celia Martinez-De Cuellar, Roberto Debbag","doi":"10.1080/14760584.2024.2395550","DOIUrl":"10.1080/14760584.2024.2395550","url":null,"abstract":"Introduction: Dengue disease represents a large and growing global threat to public health, accounting for a significant burden to health systems of endemic countries. The World Health Organization's (WHO) Strategic Advisory Group of Experts (SAGE) and the European Medicines Agency (EMA) currently recommend the use of TAK-003 dengue vaccine in high dengue burden and transmission settings for countries considering vaccination as part of their integrated management strategy for prevention and control of Dengue.Areas covered: This paper describes the main conclusions of a workshop held by the Arbovirus Committee of the Latin American Society of Pediatric Infectious Diseases (SLIPE) in November 2023, to generate consensus recommendations on the introduction of this new vaccine in the region. Considerations were made regarding the molecular epidemiology of dengue infection in the Americas and the need for more precise phylogenetic classification and correlation with clinical outcome and disease severity.Expert opinion: Introduction of dengue vaccine should be considered as an strategy for health entities in the region, with participation of social sectors, scientific societies, and ministries of health that could be able to create a successful vaccination program.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":null,"pages":null},"PeriodicalIF":5.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142016884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0